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Objective: To establish a comprehensive cancer treatment and prevention policy, data collec-
tion should be performed in a timely manner, and survival analysis needs to reflect changes
in treatment strategy. Therefore, we introduced the concept of period analysis for gastric
cancer, the most prevalent cancer in Korea. We estimated 5- and 10-year survival trend of
gastric cancer, based on data from the Yonsei Cancer Center Tumor Registry between 1990
and 2004.
Methods: We compared the differences in survival between cohort, complete and period
analyses for two different periods, 1995–99 and 2000–04.
Results: A total of 11 724 cases were included. The median age of cancer diagnosis gradu-
ally increased over time, and more patients were diagnosed with Stage I disease in recent
years. In the basic comparison of three estimated analytic methods (cohort, complete and
period), period analysis (45.8%) was most similar to the actual 5-year observed survival rate
(48.5%), when compared with cohort (43.6%) and complete (44.8%) analyses. When we
compared survival between different 10-year periods (1990–99 and 1995–2004), period
analysis demonstrated a greater difference than complete analysis (9.0 versus 3.9%).
Subgroup analysis indicated that the survival improvement was determined by period analy-
sis, and it was more pronounced for the age group ,74 years and in Stages III–IV patients.
Conclusions: We observed that period analysis demonstrates the most similar results to the
actual observed survival and is, therefore, a useful method to derive precise cancer survival
in gastric cancer. This information is useful to understand survival differences that are influ-
enced by changing treatment strategy.
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INTRODUCTION
Gastric cancer is the second most common cause of cancer-
related death worldwide (1). In particular, it is the most com-
monly diagnosed malignancy in East Asia and South
America (2). Over several decades, the survival outcome has
improved from 6–9 months to 10–12 months (3–5). Early
screening, newly developed novel chemotherapeutic agents
and improved supportive care have all played an important
role in this improvement of survival outcome. In addition to
these medical developments, accurate and comprehensive
epidemiologic information is necessary for further clinical
beneﬁts and cancer prevention. Among this information,
precise survival outcome is one of the most basic and essen-
tial statistics. For this analysis, data collection should be per-
formed in a timely manner, and survival analysis needs to
reﬂect changing trends. Several conventional methodologies
have been tested to achieve these aims.
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As one of the conventional analysis methods, the cohort
method denotes estimated cumulative survival only for
entirely followed patients; therefore, because patients who
are recently recruited or who drop-out from the study can be
censored and ignored in cohort analysis, this method results
in statistical inaccuracy. Speciﬁcally, it is less effective at
reﬂecting recent advances. To include survival experience
until the closing date of the follow-up, the Kaplan–Meier
method, also called complete analysis, is currently widely
used. Because it includes early survival experience of
recently recruited patients, this method is more compensa-
tory than cohort analysis. However, complete analysis more
dominantly estimates the longer-followed patients; therefore,
it is still not sufﬁcient to reﬂect recent advances and trends.
Hence, new methods that reﬂect recent trends and improve-
ment are needed for precise survival analysis.
Period analysis was ﬁrst introduced in 1996 by Brenner
and Gefeller and has been shown to provide more up-to-date
estimates than other traditional methods (3,4). Therefore, in
this gastric cancer study, we introduced the up-to-date esti-
mate of period analysis and compared this estimate with tra-
ditional methods. At the same time, we tried to depict the
changing trend of clinical features of gastric cancer in Korea.
PATIENTS AND METHODS
STUDY POPULATION
Our analysis is based on data from the Yonsei Cancer Center
Registry, an approximately 2000-bed major tertiary hospital
in Korea. Patients who were diagnosed with carcinoma in
situ or carcinoma were included, together with those having
brain and central nervous system tumors. Our cancer registry
receives all accrual records when cancer is diagnosed in both
outpatient and inpatient clinics. At the time of this analysis,
our database included all cancer patients diagnosed since
1980. Among the various cancer types, our study population
was gastric cancer patients aged 15 years or older with a ﬁrst
diagnosis between 1990 and 2004. Stage was not recorded
until 1995; therefore, stage analysis was performed only for
patients diagnosed after 1996. Stage registration was
recorded as initial stage at diagnosis with the American Joint
Committee on Cancer (AJCC) staging system.
Patient follow-up was efﬁciently performed using a per-
sonal identiﬁcation number. The cases were matched twice
per year with the list of deaths. These data were also
matched with the national population registries for a second
check. Because a computerized matching system was used,
only a small number of deaths were missed in our registry.
All patients in this analysis were followed until 31
December 2004.
STATISTICAL ANALYSIS
In this study, we comparatively assessed cohort, complete
and period analyses. The description of each method is
illustrated in Fig. 1. First, we set standard 5-year survival as
the observed analysis, deﬁned as patients diagnosed between
1995 and 1999 and followed for 5 years. After that, we com-
pared the observed survival with three estimated analyses
(cohort, complete and period). For the estimated 5-year sur-
vival analyses, all the patients were recruited between 1990
and 1999. For cohort analysis, the 5-year survival was esti-
mated with the patients recruited in 1990–94, and all
patients had a complete 5-year follow-up by the end of
1999. For complete analysis, all patients recruited between
1990 and 1999 were included and were observed for a
maximum 5 years. Because of these inclusions, complete
analysis would be a more precise and up-to-date analysis
than cohort analysis. However, some patients recruited
during 1995–99 would not have completed 5-year
follow-up; therefore, the complete analysis is deﬁned as
‘right censored’ observations.
Like complete analysis, period analysis was obtained from
patients recruited between 1990 and 1999. In contrast to
complete analysis, period analysis was restricted to patients
and events during a more recent period between 1995 and
1999. As well as ‘right censoring’ in the complete analysis,
this was performed by left truncation of survival experience
between 1991 and 1994 (5,6). Therefore, when compared
with other traditional analyses (cohort and complete), period
estimates reﬂect the survival experience during a more
recent period.
To verify these results over extended time, we also used a
10-year time window (1990–99 and 1995–2004). Due to the
deﬁnition of cohort analysis, 10-year survival was only avail-
able for complete and period analyses. Similar to the 5-year
survival analysis, 10-year complete analysis included
patients recruited between 1990 and 1999 with a maximum
10 years of follow-up. In addition, 10-year complete survival
was also analyzed for patients recruited between 1995 and
2004. However, extension of time windows is somewhat dif-
ﬁcult for recent cancer registries because extension requires
additional inclusion of patients diagnosed a long time ago.
Therefore, we used abbreviated-period modeling which
needs a minimum number of 1-year cohorts for analysis, as
shown in a previous study (7). Instead of conventional
period analysis, which uses a full 5- or 10-year period, this
modiﬁed period analysis uses the single most recent year.
Therefore, for the period analysis, we estimated the abbre-
viated period between the most recent single year 1999
(1990–99) and 2004 (1995–2004) for 10-year survival
(dotted box in Fig. 1).
RESULTS
DEMOGRAPHICS
A total of 11 724 cases were included in this analysis.
Between 1990 and 2004, approximately two-thirds of
patients were male, with a constant male/female ratio (7917
male and 3807 female). Figure 2 depicts the changes in age
Jpn J Clin Oncol 2011;41(12) 1345
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on N
ovem
ber 13, 2013
http://jjco.oxfordjournals.org/
D
ow
nloaded from
 
and stage distribution. The median age for all the patients
was 56.4 (range 15–94). The median age in 1990 was 54.7
years and gradually increased to 58.0 years in 2004. Among
all of the patients, 4629 (39.6%) were 0–54 years old, 3795
(32.4%) were 55–64 years old, 2662 (22.7%) were 65–74
years and 628 (5.4%) were 75 years or older. As shown in
Fig. 2A, the proportion of patients ,54 years old and those
between 55 and 64 years decreased from 45.0 to 36.2% and
from 30.8 to 28.8%, respectively. Conversely, the proportion
of patients between 65 and 74 years old and those older than
75 years increased from 21.4 to 28.4%, and from 2.9 to
6.6%, respectively. In terms of stage at diagnosis, 2839
(33.6%) were Stage I, 899 (10.6%) Stage II, 1653 (19.6%)
Stage III, 2005 (23.7%) Stage IV and 1058 (12.5%) patients
were unknown stage. The proportion of patients with Stage I
disease in 1996 was 24.6% and increased 2-fold up to
40.0% in 2004. In contrast, the proportion with Stage IV
disease was 29.1% in 1996 and decreased to 22.4% in 2004
(Fig. 2B).
COMPARISON OF ANALYTIC METHODS (COHORT, COMPLETE AND
PERIOD)
The results of 5-year cumulative overall survival (OS) by
each method are shown in Fig. 3. The observed 5-year survi-
val during 1995–99 was 48.5%. The estimated 5-year
survival for cohort, complete and period analyses was 43.6,
44.8 and 45.8%, respectively. The discrepancies between
observed survival and estimated survival were 4.9, 3.7 and
2.7 for cohort, complete and period analyses, respectively.
Therefore, the estimated period analysis demonstrated the
most similar results to the observed survival.
We also assessed the 5-year survival differences among
patients diagnosed during the more recent period of 1995–
2004. The estimated 5-year survival analyses for this period
demonstrated a similar tendency of improved accuracy with
period analysis. The estimated 5-year survival for cohort,
complete and period analyses during 1995–2004 were 48.5,
51.2 and 54.2%, respectively (Table 1). When we adjusted
for other causes of death, deﬁned as relative survival (RS),
period analysis still yielded the highest cumulative survival
estimates (59.3%, 95% conﬁdence interval 57.7–60.8)
during this period, as shown in Table 1. We also compared
age or stage-speciﬁc 5-year survival rates of each analysis
during the period 1995–2004. For Stages I– II patients, the
three analytic methods showed almost similar survival rates.
However, for patients with Stages III– IV, period analyses
demonstrated better survival outcome than complete and
cohort analyses. In age-speciﬁc 5-year survival analyses, for
patients ,74 years old, 5-year survival by period analysis
also showed higher survival rates than complete analysis,
and cohort analysis demonstrated the lowest survival rate.
Figure 1. Differences of cohort, complete and period analyses for 5-year survival curves. Patients were recruited during 1990–99 and followed until 2004
according to the types of analysis. The numbers within cells indicate years following diagnosis.
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However, for patients 75 years or older, the three methods
showed similar results. In addition, in gender-speciﬁc 5-year
survival, period analysis also showed higher survival rates
than complete analysis, and cohort analysis demonstrated the
lowest survival rate.
In addition, as shown in Fig. 4, the discrepancies in RS
between each analysis showed the same tendency over time.
The difference between these three analyses, observed from
the ﬁrst year, became more prominent over time up to 3
years, and then continued until the 5-year follow-up visit.
Thus, cohort, complete and period analyses demonstrated
75.9, 78.3 and 80.5% for 1-year RS rates and 58.3, 61.4 and
64.4% for 3-year survival rates, respectively.
PERIOD ANALYSES OF 5- AND 10-YEAR DURATION
To verify whether period analysis showed the same pattern
over a more extended period, we also assessed 10-year survi-
val rates with those methods. Because cohort analysis needs
at least 10 years of follow-up after the last enrollment, it was
not possible to obtain 10-year OS by cohort analyses. For
both complete and period analyses, the 10-year survival rates
were generally lower than 5-year survival rates (Table 2). In
complete analysis, the 5-year and 10-year RS in 2004 was
56.1 and 42.9%, respectively. Similarly, by period analysis,
the 5-year RS in 2004 was 59.3% and the 10-year RS was
48.8%.
In addition, in terms of 10-year RS changes between
1990–99 and 1995–2004, period analysis demonstrated
greater differences than complete analysis (Fig. 5A). The
difference in 10-year survival rate for all patients between
1990–99 and 1995–2004 was 3.9% by complete analysis,
when compared with 9.0% for abbreviated period analysis.
Therefore, for recent changes in difference between 2004
and 1999, 10-year period analysis demonstrated a greater
difference than complete analysis.
Figure 2. Changes in age (A) and stage (B) distribution.
Figure 3. Comparisons of 5-year cumulative survival estimates by type of
analyses during period 1990–99.
Table 1. Comparisons of 5-year cumulative survival estimates by type of
analyses during 1995–2004
Follow up year Cohort Complete Period
5-year OS 48.5 51.2 54.2
5-year RS (95% CI) 53.2
(51.5–55.0)
56.1
(54.7–57.4)
59.3
(57.7–60.8)
Stage
I (n ¼ 2839, 33.6%) 92.9 92.5 92.6
II (n ¼ 899, 10.6%) 72.4 72.4 73.8
III (n ¼ 1653, 19.6%) 44.3 44.9 45.9
IV (n ¼ 2005, 23.7%) 5.0 5.3 5.5
Age
0–54 (n ¼ 4629, 39.6%) 52.7 55.9 59.5
55–64 (n ¼ 3795, 32.4%) 50.7 54 58.1
65–74 (n ¼ 2662, 22.7%) 41.8 44.6 47.4
75 (n ¼ 628, 5.4%) 29.8 30.6 30
Gender
Male 42.9 44 44.7
Female 45.1 46.6 48
OS, overall survival; RS, relative survival; CI, conﬁdence interval.
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We also performed a more detailed period analysis in
terms of gender and age. The survival improvement for
period analysis was two times more prominent for male
patients than female patients (Fig. 5B). For the comparison
of 10-year OS with respect to age category, the difference
between the two analytic methods was more prominent for
the age group ,74 years (107–221% increment) than for
those 75 years old (54% increment).
DISCUSSION
In this study, we precisely compared various different ana-
lytic methods using a large gastric cancer database. We
identiﬁed period analysis as a useful, up-to-date and precise
method that reﬂects the recently improved survival. In
addition, because gastric cancer is the most commonly diag-
nosed malignancy in Korea, this result has more power to
conﬁrm the analytic advantages.
We analyzed patients who were diagnosed between 1990
and 2004. Our hospital is a 2000-bed tertiary hospital with a
long history of comprehensive cancer care, and more than
10 000 new cancer patients are registered every year. We
have been using standard international classiﬁcation of
disease for oncology tumor classiﬁcation. In addition, regis-
tration information was obtained as a standardized method
with AJCC, International Federation of Gynaecology and
Obstetrics (FIGO) (for cervical cancer) and DUKE staging
systems. The follow-up rate of our tumor registry is .90%,
with only a low number of losses. These factors make our
tumor registry reliable and objective.
First of all, we depicted the changing trend of gastric
cancer with respect to stage and age distribution. The pro-
portion of patients diagnosed with Stage I increased from
24.6% in 1996 to 40.0% in 2004. Since 1996, an active
health care strategy, especially for gastric, breast and cervical
cancer, was applied as part of a national cancer screening
program in Korea (8). Therefore, this shift to an earlier stage
might be attributed to the introduction of national preventive
education/programs and improvement of the screening
method of esophagoduodenoscopy. In addition to the stage,
age distribution also changed over this period; the proportion
of patients younger than 65 years decreased, whereas the
proportion of elderly patients increased. These results are
similar to those of previous studies (9,10), and may reﬂect
the life span extension in the general population. This
pattern is expected to continue in the future because of
widely available new screening and detection methods.
Brenner and Gefeller (6) ﬁrst suggested the usefulness
of the period analytic method in 1997. In their study, they
Figure 4. Five-year relative survival (RS) estimates according to follow-up
period by type of analyses.
Table 2. Comparisons of 10-year survival outcomes between complete and period analyses
Complete Period Change difference
(period-complete, % unit)
1999 2004 Change
(1999 versus 2004)
1999 2004 Change
(1999 versus 2004)
10-year RS 39 42.9 3.9 39.8 48.8 9 5.1 (131)
Gender
Male 38.4 41.2 2.8 38.9 46.9 8.0 5.2 (186)
Female 40.3 46.4 6.1 41.5 51.5 10.0 3.9 (64)
Age
0–54 44.0 51.0 7.0 44.9 59.4 14.5 7.5 (107)
55–64 39.7 45.8 6.1 40.9 53.4 12.5 6.4 (105)
65–74 32.6 34.0 1.4 33.5 38.0 4.5 3.1 (221)
75 3.8 8.8 5.0 0.0 7.7 7.7 2.7 (54)
10-year RS: 1999–2004.
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assessed the 5-year cumulative survival of testicular cancer
patients who were diagnosed in 1978–87, with a particular
focus on patients diagnosed in 1978, when new thera-
peutic regimens for testicular cancer became available.
The study showed that period analysis yields higher survi-
val estimates than the other types of analysis and reﬂects
recent therapeutic improvements. Subsequently, several
studies in different geographic areas have demonstrated
similar results for various cancer types (11–14). As in
these previous studies, we also compared 5-year survival
of gastric cancer patients with cohort, complete and period
analyses. Among these three estimates, period analysis
showed the most similar results to the actual observed sur-
vival, and this ﬁnding implies that period analysis
achieves the most up-to-date estimates. With period analy-
sis, information from the most recent period of interest is
included, and survival from the other duration is dis-
carded. As a result, period analysis provides long-term
survival estimates with consideration of more recently
diagnosed and treated patients. In our comparison, period
analysis best reﬂected trends over time and also implied
that gastric cancer survival outcome has further improved
in recent years. Therefore, our study indicates that period
analysis may be the most useful to estimate recent trends
of cancer survival, as shown in previous studies (3,7).
For period analysis, one of the remaining questions is the
optimal time period that best reﬂects tumor biology and
treatment modality. The comparisons between 5- and
10-year periods further clariﬁed the advantage of period
analysis in these gastric cancer cases. In a previous study,
compared with period analysis of a 5-year time window,
10-year period analysis provided more precise and accurate
survival data by reducing the standard errors of survival esti-
mates (7), and a 10 year duration was accepted as a desirable
option in gastric cancer survival analysis. Brenner and
Gefeller also suggested that further beneﬁts in cancer survi-
val could be obtained with an extended time window. In
addition, in this study, an abbreviated 10-year period analysis
enabled wider period estimates without additional numbers
of patients. Further studies on the optimal length of time
windows in the various disease entities are needed to vali-
date this result.
In addition to overall distribution, we also assessed the
changes in survival with respect to age and stage distri-
bution. Interestingly, survival improvement with period
analysis was most prominent in patients ,74-years-old, and
somewhat lower in elderly patients, for both 5- and 10-year
survival rates, as shown in previous studies (15–17). One of
the reasons for this ﬁnding is the increased prevalence of
co-morbidities that negatively affect diagnostic and thera-
peutic choices (18). Biologically different clinicopathologi-
cal features of gastric cancer in the elderly may be another
explanation. Elderly patients have been shown to have much
higher rates of advanced stage and multiple gastric cancers
in previous studies (9,19,20). In addition, elderly patients are
less likely to receive aggressive therapies (surgical manage-
ment, chemotherapy and radiotherapy) than younger patients
(16,21,22), and are usually not eligible to be included in
clinical trials. Therefore, considering the fact that age distri-
bution at diagnosis has shifted to higher ages, a desirable
diagnostic and therapeutic strategy is necessary for this
rapidly increasing population of elderly patients, and this
kind of age-speciﬁc analysis may provide useful information
for further studies.
Signiﬁcant survival difference between male and female
has been reported in several gastrointestinal tumors. In the
stomach cancer patients, age-standardized death rate for
gastric cancer was worse for male patients (23). One poss-
ible explanation of survival may be explained by the differ-
ent life expectancy between two groups. In the 2005 registry,
males live 75.1 years, whereas females live 81.9 years. This
longer life expectancy may cause longer survival of female
patients. However, the other biologic factors such as sex
hormone or immunologic effect should be researched with
further prospective studies.
For the analysis according to the stage distribution, survi-
val improvement of period analysis was not evident for the
Stages I–II patients. However, survival rate in period analy-
sis was deﬁnitely improved for the Stages III– IV patients.
As an explanation, effective chemotherapy and supportive
care have developed remarkably during this period. In
addition, several novel agents, such as irinotecan, oral 5-
ﬂuorouracil and molecularly targeted agents, have demon-
strated activity with tolerable toxicities (24–26). Therefore,
the recent advances of chemotherapy and supportive care
Figure 5. Comparisons of 10-year survival outcomes between complete and
period analyses (A) and gender differences (B).
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may signiﬁcantly inﬂuence the survival outcome of patients
with an advanced stage of disease.
Despite these advantages of period analysis, there are
several limitations in this report. First of all, this result was
deduced from a single-center cancer registry. Because our
center is a tertiary center, the majority of patients were trans-
ferred from local clinics when their disease progressed to an
advanced stage, even though their initial disease status was
early stage. Secondly, we only analyzed disease status and
survival outcome without any detailed information about
treatment, which might affect the survival outcome. Patients
who received active treatment and those with only supportive
care were all analyzed together. Therefore, the effect of
treatment was only indirectly reﬂected in these results.
Third, patients who may have more than two types of cancer
were included repeatedly in this analysis. According to our
previous research on the seven most common cancers
(stomach, liver, lung, colon, cervix, breast and thyroid)
between 1995 and 2004, 541 of 34 217 cases (1.6%) were
duplicated due to double or triple cancer types. Fourth, for
the period analysis, there is some risk of survival mispredic-
tion if the data set is from the too small or immature popu-
lation, or survival has not changed a lot. Therefore, it is not
feasible to apply period analysis for cases of rare tumor
types. For this reason, we applied this method to gastric
cancer, which is the most prevalent malignancy with sufﬁ-
cient numbers of patients.
In conclusion, we observed that period analysis is a very
useful method to derive precise survival rates in gastric
cancer. Our study also described changing trends of long-
term survival for different age groups using period analyses.
A combination of well-established data and the analytic
methodology of period analysis provide the most up-to-date
information. This reliable baseline information may help to
predict and establish proper health policy in the future. To
our knowledge, this is the ﬁrst comprehensive evaluation
with the most up-to-date survival estimates for one of the
more major cancers in a highly prevalent area. Moreover,
this information might be useful in order to understand the
survival differences resulting from a change in treatment
strategy.
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